Similar efficacy and safety of LY2963016 insulin glargine and insulin glargine (Lantus®) in patients with type 2 diabetes who were insulin-naïve or previously treated with insulin glargine: A randomized, double-blind controlled trial (the ELEMENT 2 study)

Diabetes, Obesity and Metabolism

Volumn 17, Issue 8, 2015, Pages 734-741

  Rosenstock, J ^a   Hollander, P ^b   Bhargava, A ^c   Ilag, L L ^d   Pollom, R K ^d   Zielonka, J S ^d   Huster, W J ^d   Prince, M J ^d  

^a DALLAS DIABETES AND ENDOCRINE CENTER AT MEDICAL CITY   (United States)

^b Baylor Endocrine Center   (United States)

^c Iowa Diabetes and Endocrinology Center   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Insulin glargine; Insulin naive; LY2963016; Type 2 diabetes

Indexed keywords

GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; INSULIN GLARGINE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; HEMOGLOBIN A1C PROTEIN, HUMAN; LY2963016 INSULIN GLARGINE;

ADULT; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; ASTHMA; CONTROLLED STUDY; DERMATITIS; DIABETIC PATIENT; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION SITE INDURATION; INJECTION SITE PRURITUS; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; NOSE EDEMA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PERIARTHRITIS; PHASE 3 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; WEIGHT CHANGE; AGED; ANALOGS AND DERIVATIVES; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DIET RESTRICTION; DRUG EFFECTS; MIDDLE AGED; PROCEDURES;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FASTING; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN ANTIBODIES; INSULIN GLARGINE; MALE; MIDDLE AGED;

EID: 84937817049     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12482     Document Type: Article

References (32)

1. Niswender K. Early and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence? Clin Diabetes 2009; 27: 60-68.
2. Inzucchi SE, Bergenstal RM, Buse JB etal. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012; 55: 1577-1596.
3. Riddle MC, Rosenstock J, Gerich J, Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
4. Rosenstock J, Dailey G, Massi-Benedetti M etal. Reduced hypoglycemia risk with insulin glargine: a meta-analysis comparing insulin glargine with human NPH insulin in type 2 diabetes. Diabetes Care 2005; 28: 950-955.
5. Rosenstock J, Fonseca V, Schinzel S etal. Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: evidence from a long-term controlled trial. J Diabetes Complications 2014; 28: 742-749.
6. Yki-Jarvinen H, Dressler A, Ziemen M, HOE 901/3002 Study Group. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130-1136.
7. Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M etal. Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. Diabetologia 2006; 49: 442-451.
8. European Medicines Agency. Abasaglar (previously Abasria). 2014. Available from URL: http://www.ema.europa.eu/ema/index.jsp?curl=/pages/medicines/human/medicines/002835/human_med_001790.jsp&mid=WC0b01ac058001d124. Accessed 31 March 2015.
9. European Medicines Agency. European public assessment report: Abasria. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002835/WC500175383.pdf. Accessed 31 March 2015.
10. Food and Drug Administration. Drug approval package: Lantus (insulin glargine [rDNA origin]) NDA #21-081. 2000. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2000/21081_Lantus.cfm. Accessed 31 March 2015.
11. Eli Lilly and Company. FDA grants tentative approval for Lilly and Boehringer Ingelheim's Basaglar™ (insulin glargine injection). 2014. Available from URL: https://investor.lilly.com/releasedetail.cfm?ReleaseID=866751. Accessed 31 March 2015.
12. Food and Drug Administration. Biologics Price Competition and Innovation Act. 2009. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/UCM216146.pdf. Accessed 31 March 2015.
13. European Medicines Agency. Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (revision 1). 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/06/WC500167838.pdf. Accessed 31 March 2015.
14. European Medicines Agency. Committee for medicinal products for human use. Guideline on similar biological medicinal products. 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003517.pdf. Accessed 31 March 2015.
15. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. 2014. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/04/WC500165988.pdf. Accessed 31 March 2015.
16. Food and Drug Administration. Guidance for industry: clinical pharmacology data to support a demonstration of biosimilarity to a reference product. 2014. Available from URL: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM397017.pdf. Accessed 31 March 2015.
17. World Health Organization. Expert committee on biological standardization. Guidelines on evaluation of Similar Biotherapeutic Products (SBPs). 2009. Available from URL: http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 31 March 2015.
18. Byrd RA, Blackbourne JL, Schultze AE, Vahle JL. Comparative subchronic toxicity studies in rats of LY2963016 (LY), an insulin glargine product, with USA sourced Lantus® (US-L) and EU-sourced Lantus® (EU-L). Toxicologist 2014; 138: 1650.
19. Heise T, Zhang X, Quin Lam EC etal. Duration of action of 2 insulin glargine products, LY2963016 and Lantus®, in subjects with type I diabetes mellitus (T1DM). Diabetes 2014; 63(Suppl. 1): 891-P.
20. Linnebjerg H, Quin Lam EC, Seger ME etal. Comparative pharmacokinetics (PK) and pharmacodynamics (PD) of LY2963016 insulin glargine and EU- and U.S.-approved versions of Lantus® insulin glargine in healthy subjects. Diabetes 2014; 63(Suppl. 1): 889-P.
21. Zhang X, Quin Lam EC, Seger ME etal. Comparative pharmacokinetics and pharmacodynamics of two insulin glargine products, LY2963016 and Lantus®, in healthy subjects at two dose levels. Diabetes 2014; 63(Suppl. 1): 890-P.
22. ®) in patients with type 1 diabetes in a randomised controlled trial (The ELEMENT 1 Study). Diabetes, Obesity and Metabolism 2015; 17: 726-733.
23. World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925-926.
24. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Report of a WHO Consultation. 1999. Available from URL: http://apps.who.int/iris/bitstream/10665/66040/1/WHO_NCD_NCS_99.2.pdf?ua=1. Accessed 15 October 2014.
25. Gerstein HC, Yale JF, Harris SB etal. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. Diabet Med 2006; 23: 736-742.
26. European Medicines Agency. Guideline on the choice of the non-inferiority margin. 2005. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003636.pdf. Accessed 15 October 2014.
27. Food and Drug Administration. Guidance for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Draft guidance February 2008. Available from URL: http://www.fda.gov/downloads/Drugs/Guidances/ucm071624.pdf. Accessed 1 April 2015.
28. Food and Drug Administration. Guidance for industry: non-inferiority clinical trials. Draft guidance March 2010. 2010. Available from URL: http://www.fda.gov/downloads/Drugs/./Guidances/UCM202140.pdf. Accessed 1 April 2015.
29. Food and Drug Administration. Guidance for industry: Quality considerations in demonstrating biosimilarity to a reference protein product. 2012. Available from URL: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf. Accessed 26 March 2015.
30. LANTUS- insulin glargine injection, solution. Drug label information. 2015. Available from URL: http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5e07a0c-7e14-4756-9152-9fea485d654a. Accessed 1 April 2015.
31. European Medicines Agency. LANTUS: EPAR - Product information. 2015. Available from URL: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000284/WC500036082.pdf. Accessed 1 April 2015.
32. Meneghini L, Atkin SL, Gough SC etal. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individuals with type 2 diabetes. Diabetes Care 2013; 36: 858-864.